DelveInsight’s “Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Generalized Anxiety Disorder market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Generalized Anxiety Disorder market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Generalized Anxiety Disorder: An Overview
Generalized Anxiety Disorder (GAD) is characterized by persistent, excessive, and unrealistic worry about everyday things. This worry could be multifocal, such as finance, family, health, and the future. It is, in excess, difficult to control and often accompanied by many nonspecific psychological and physical symptoms. Excessive worry is the central feature of Generalized Anxiety Disorder.
The criteria of Generalized Anxiety Disorder in DSM-V include the characteristics such as feeling restless, keyed up, or on edge, fatiguing easily, having difficulty concentrating or the mind going blank, irritability, increased muscle tension, difficulty falling asleep, staying asleep, or restlessness. Excessive worry and anxiety occur most of the time for at least 6 months, with at least three of the core symptoms in adults and one sign in the case of children.
Generalized Anxiety Disorder Market Key Facts
-
The total 12-month prevalent patient population of Generalized Anxiety Disorder in the 7MM countries was close to 16 million cases in 2021.
-
The Generalized Anxiety Disorder market size in the seven major markets was approximately USD 1,500 million in 2021, which is expected to grow by 2032.
-
According to the Anxiety and Depression Association of America (ADAA), in any given year, GAD affects 6.8 million adults or 3.1% of the US population.
-
Women are twice as likely to be affected by Generalized Anxiety Disorder. Although the exact cause of GAD is unknown, there is evidence that biological factors, family background, and life experiences, particularly stressful ones, play a role.
-
Several companies are working robustly on many new therapies, such as MM-120 (Mind Med) and PH49B (VistaGen’s Therapeutics). The mid-stage pipeline is crowded, with several potential therapies with the imminent attention of big pharmaceutical companies for this market space.
Generalized Anxiety Disorder Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Generalized Anxiety Disorder market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Generalized Anxiety Disorder market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Generalized Anxiety Disorder Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
The Report Covers the Generalized Anxiety Disorder Epidemiology Segmented by –
-
Total 12-Month Prevalent Cases of Generalized Anxiety Disorder
-
Gender-specific Cases of Generalized Anxiety Disorder
-
Age-Specific Cases of Generalized Anxiety Disorder
-
Severity-Specific Cases of Generalized Anxiety Disorder
Generalized Anxiety Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Generalized Anxiety Disorder market or expected to get launched during the study period. The analysis covers the Generalized Anxiety Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Generalized Anxiety Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Generalized Anxiety Disorder Market Will Evolve by 2032:
https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market
Some of the key companies in the Generalized Anxiety Disorder Therapeutics Market include:
-
Bionomics
-
Sage Therapeutics
-
VistaGen Therapeutics
-
Fabre-Kramer Pharmaceuticals
-
Forest Laboratories
-
Allergan
-
MindMed
-
VistaGen Therapeutics
-
Actavis
-
Takeda Pharmaceuticals
And others
Generalized Anxiety Disorder Therapies Covered in the report include:
-
BNC210
-
Travivo
-
SAGE-217
-
PH94B
-
Vilazodone
And many more.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Generalized Anxiety Disorder Competitive Intelligence Analysis
4. Generalized Anxiety Disorder Market Overview at a Glance
5. Generalized Anxiety Disorder Disease Background and Overview
6. Generalized Anxiety Disorder Patient Journey
7. Generalized Anxiety Disorder Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Generalized Anxiety Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Generalized Anxiety Disorder Unmet Needs
10. Key Endpoints of Generalized Anxiety Disorder Treatment
11. Generalized Anxiety Disorder Marketed Products
12. Generalized Anxiety Disorder Emerging Drugs and Latest Therapeutic Advances
13. Generalized Anxiety Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Generalized Anxiety Disorder Market Outlook (In US, EU5, and Japan)
16. Generalized Anxiety Disorder Access and Reimbursement Overview
17. KOL Views on the Generalized Anxiety Disorder Market
18. Generalized Anxiety Disorder Market Drivers
19. Generalized Anxiety Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Generalized Anxiety Disorder Pipeline Insights
“Generalized Anxiety Disorder Pipeline Insight, 2022″ report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Generalized Anxiety Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/